Leflunomide Zentiva

Leflunomide, the active ingredient in Leflunomide Zentiva, is a disease-modifying antirheumatic drug (DMARD) presented as a tablet for oral use. It is used to treat rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce inflammation and slow disease progression.

GNH USA supplies Leflunomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable sourcing for therapeutic needs across multiple continents and regulatory jurisdictions, with dedicated customer support.

Leflunomide is a disease-modifying antirheumatic drug that targets immune‑mediated joint inflammation.

Rheumatoid arthritis: reduces joint swelling, pain and slows radiographic progression. Psoriatic arthritis: improves skin lesions and joint symptoms. Moderate to severe rheumatoid arthritis refractory to methotrexate: provides clinical improvement when other DMARDs are insufficient.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: loose stools often mild to moderate. - Nausea: feeling of sickness. - Elevated liver enzymes: mild increase in ALT/AST. - Hypertension: rise in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Aplastic anemia: bone marrow suppression leading to low blood counts. - Stevens‑Johnson syndrome: severe skin reaction with blistering.

Before prescribing Leflunomide, clinicians should consider several safety factors.

Pregnancy: contraindicated (Category X) – avoid use in pregnant women. Liver disease: contraindicated; assess liver function before initiation. Renal impairment: use with caution; dose may need adjustment. Infection risk: monitor for signs of infection; avoid in active infections. Blood monitoring: perform regular CBC and liver tests during therapy. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, may require dose adjustment. - Methotrexate: additive hepatotoxicity, monitor liver function closely. - Cholestyramine or activated charcoal: reduce leflunomide plasma levels, avoid co‑administration.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): decrease leflunomide exposure. - TNF‑α inhibitors: may reduce efficacy, monitor disease activity. - Azathioprine: increased risk of bone marrow suppression.